774544-68-2

Upstream product

• 2646-30-2 1-(4-bromophenyl)thiourea 
• 621-62-5 chloroacetaldehyde diethyl acetal 

Relevant academic research and scientific papers

Molecular docking and glucosidase inhibition studies of novel N-arylthiazole-2-amines and Ethyl 2-[aryl(thiazol-2-yl)amino]acetates

This study describes an efficient synthesis of a series of novel ethyl 2-[aryl(thiazol-2-yl)amino]acetates (4a–l) from N-arylthiazole-2-amines (3a–l). The reaction conditions were optimized and the best results were obtained when ethyl chloroacetate was used as alkylating agent and NaH as base in THF. α-glucosidase and β-glucosidase inhibition activities of N-arylthiazole-2-amines (3a–l) and ethyl 2-[aryl(thiazol-2-yl)amino]acetates (4a–l) were determined, which revealed that most of the compounds showed high percentage inhibition towards the enzymes. Among the synthesized compounds, 4e appeared to have the highest inhibition towards α-glucosidase having IC50 value of 150.4 ± 1.9 μM which was almost two folds as compared to acarbose (336.9 ± 9.0 μM) taken as standard. Molecular docking of the compounds 3g, 3f, 4a, and 4e was also performed which showed their bonding modes to the enzyme’s active sites via amino and acetate groups, respectively.

Cholinesterase inhibitory activities of N-phenylthiazol-2-amine derivatives and their molecular docking studies

Alzheimer's disease (AD) is a type of neurodegenerative disorder which is responsible for many cognitive dysfunctions. According to the most accepted cholinergic hypothesis, cholinesterases have a major role in AD symptoms. The use of small molecules as inhibitors is one of the most useful strategies to control AD. In the present work, a series of N-phenylthiazol-2-amine derivatives was screened against acetylcholinesterase (AChE) from Electrophorus electricus and butyrylcholinesterase (BChE) from horse serum by using Ellman's method, using neostigmine and donepezil as reference drugs. Some of the assayed compounds proved to be potent inhibitors for AChE and BChE activity. N-(2,3-dimethylphenyl)thiazol-2-amine, 3j was found to be the most active inhibitor among the series with IC50 value of 0.009 ± 0.002 μM and 0.646 ± 0.012 μM against AChE and BChE, respectively. Molecular docking studies were carried out in order to better understand the ligand binding site interactions.

Synthesis, characterization and density functional theory study of some new 2-anilinothiazoles

We report here a comparative theoretical and experimental study of anilinothiazoles. The anilinothiazoles are synthesized by acid catalyzed condensation of N-phenylthioureas and 2-chloro-1,1-dimethoxyethane. Substituted anilines were employed to introduce substitution in 2-anilinothiazoles. The experimental geometric and spectroscopic properties of the anilinothiazoles are compared with the theoretically calculated ones. The model developed here comprises of geometry optimization at B3LYP method of DFT at 6-31+G(d) basis set. The optimized geometric parameters of anilinothiazoles show nice correlations with values obtained from X-ray crystal structure. Differences of up to 0.02 ? in bond length and 1.0° in bond angles are observed except SC2N6 and C7N6C2 where this difference is 1.77°and 6.01°, respectively. The vibrational spectra are calibrated with a common scaling factor of 0.9613 and show nice correlations with the experimental IR spectra. The UV-Vis spectra calculated at 190-450 nm range show 20-25 nm difference from the experimental spectra. The consistent difference may be attributed to the condensed phase nature of anilinothiazoles however the theoretical spectra are for single molecules. In addition HOMO, LUMO and the associated band gaps are also calculated and depicted.

NOVEL HETEROARYL-AMINO DERIVATIVES

Disclosed is a compound of formula (I), wherein R1, R2, L, Rm and Rn are as defined herein. The compound of formula (I) may be used in preventing and/or treating acyl CoA-diacylglycerol acyltransferase 1(DGAT-1) related diseases, such as obesity, coronary disease, hypertension, hyperlipidemia, arteriosclerosis, type II diabetes, stroke, hepatitis C, and the like.